fig2
![Cathepsin C: structure, function, and pharmacological targeting](https://image.oaes.cc/48c074cc-a657-4748-ad9d-b587207c82ac/rdodj2009.fig.2.jpg)
Figure 2. Reversible nitrile warhead-containing inhibitors of cathepsin C. (A) Chemical structure of compounds AZD5258 developed by AstraZeneca; (B) Crystal structure of AZDB5248 bound into the active site of cathepsin C. (PDB accession code 4CDE); (C) Chemical structure of the IcatCXPZ-01 analog used for crystallization; (D) Crystal structure of IcatCXPZ-01 analog bound into the active site of cathepsin C (PDB accession code 6IC6). Chemical structures were drawn with ChemDraw software. The crystal structures in panels B and D were drawn with UCSF Chimera software[113].